NCT06839976View on ClinicalTrials.gov

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2030

Conditions
SLESystemic Lupus Erythematosus (SLE)CAR T CellCART19Cell TherapyLupusLupus Nephritis (LN)
Interventions
BIOLOGICAL

CART19

CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Children's Hospital of Philadelphia

OTHER